JP2023508360A - Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法 - Google Patents

Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法 Download PDF

Info

Publication number
JP2023508360A
JP2023508360A JP2022538719A JP2022538719A JP2023508360A JP 2023508360 A JP2023508360 A JP 2023508360A JP 2022538719 A JP2022538719 A JP 2022538719A JP 2022538719 A JP2022538719 A JP 2022538719A JP 2023508360 A JP2023508360 A JP 2023508360A
Authority
JP
Japan
Prior art keywords
antibody
antigen
subject
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508360A5 (enExample
Inventor
エレーヌ・グラウイク
エル－バダウイ・ハダッド
サラ・ハモン
シヴァン・ハレル
ジョージオス・カリオリアス
マルセラ・ルディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023508360A publication Critical patent/JP2023508360A/ja
Publication of JP2023508360A5 publication Critical patent/JP2023508360A5/ja
Priority to JP2025283256A priority Critical patent/JP2026068738A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022538719A 2019-12-23 2020-12-22 Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法 Pending JP2023508360A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025283256A JP2026068738A (ja) 2019-12-23 2025-12-26 Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962952996P 2019-12-23 2019-12-23
US62/952,996 2019-12-23
US202062964970P 2020-01-23 2020-01-23
US62/964,970 2020-01-23
PCT/US2020/066559 WO2021133776A1 (en) 2019-12-23 2020-12-22 Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025283256A Division JP2026068738A (ja) 2019-12-23 2025-12-26 Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法

Publications (2)

Publication Number Publication Date
JP2023508360A true JP2023508360A (ja) 2023-03-02
JP2023508360A5 JP2023508360A5 (enExample) 2023-12-28

Family

ID=74191948

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538719A Pending JP2023508360A (ja) 2019-12-23 2020-12-22 Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法
JP2025283256A Pending JP2026068738A (ja) 2019-12-23 2025-12-26 Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025283256A Pending JP2026068738A (ja) 2019-12-23 2025-12-26 Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法

Country Status (11)

Country Link
US (1) US20230340101A1 (enExample)
EP (1) EP4081544A1 (enExample)
JP (2) JP2023508360A (enExample)
KR (1) KR20220119446A (enExample)
CN (1) CN115151568A (enExample)
AU (1) AU2020415382A1 (enExample)
BR (1) BR112022011388A2 (enExample)
CA (1) CA3162507A1 (enExample)
IL (1) IL294066A (enExample)
MX (1) MX2022007958A (enExample)
WO (1) WO2021133776A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
CA3236201A1 (en) * 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)
KR20250017964A (ko) * 2023-07-28 2025-02-04 재단법인 아산사회복지재단 혈액 단백체를 이용한 생물학적 제제에 대한 천식 치료 반응성 예측을 위한 바이오마커 및 이의 용도
WO2025088063A2 (en) * 2023-10-24 2025-05-01 Sanofi Systems and methods for monitoring a medicament dosing schedule
CN117949666B (zh) * 2024-01-12 2025-07-15 首都医科大学附属北京同仁医院 一种预测或评估抗IL-4Rα单抗在治疗鼻黏膜2型炎症相关鼻病疗效的标志物、方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102597A1 (en) * 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
AR108263A1 (es) * 2016-05-03 2018-08-01 Bayer Pharma AG Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
HUE067888T2 (hu) * 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
BR112022000740A2 (pt) * 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102597A1 (en) * 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory conditions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHEM BIOPHYS RES COMMUN., vol. 386, JPN6024048362, 2009, pages 181 - 185, ISSN: 0005677483 *
EUR J IMMUNOL., vol. 41, JPN6024048360, 2011, pages 1675 - 1686, ISSN: 0005677485 *
EXPERIMENTAL LUNG RESEARCH, vol. 40, JPN6024048361, 2014, pages 66 - 76, ISSN: 0005677484 *
IMMUNITY, vol. 42, JPN6024048363, 2015, pages 294 - 308, ISSN: 0005677482 *

Also Published As

Publication number Publication date
MX2022007958A (es) 2022-10-07
CN115151568A (zh) 2022-10-04
JP2026068738A (ja) 2026-04-22
BR112022011388A2 (pt) 2022-08-30
AU2020415382A1 (en) 2022-08-18
CA3162507A1 (en) 2021-07-01
EP4081544A1 (en) 2022-11-02
KR20220119446A (ko) 2022-08-29
IL294066A (en) 2022-08-01
US20230340101A1 (en) 2023-10-26
WO2021133776A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
JP7695298B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP7609901B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
JP2023508360A (ja) Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法
JP2022530533A (ja) Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法
JP2023505215A (ja) Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
JP7216157B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
EA050548B1 (ru) Способы лечения или предупреждения аллергической астмы посредством введения антагониста il-33 и/или антагониста il-4r
HK40106058A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40076109B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40076109A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40006965A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40006965B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK1211605B (en) Methods for treating or preventing asthma by administering an il-4r antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902